NeuroPhage Pharmaceuticals, a privately held biotechnology company focused on the treatment and prevention of neurodegenerative diseases, announced that it has secured $9 million. The funding round that was completed by existing investors and private investors brings the total amount of equity capital raised by NeuroPhage since its inception in 2006 to $28.6 million. NeuroPhage, which focuses on treating diseases involving protein aggregation, was founded in 2007 by a Cambridge-based team along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments